Breast cancer research program support services for congressionally directed medical research programs
Ended Awarded Last action
- Contract number
- HT942524F0281
- Awardee
-
Leidos, Inc. UEI QLNMVC12KWY3 Part of Leidos Holdings, Inc.
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $571,801
Award facts
- Opportunity
-
- Meeting, Programmatic, and Administrative Support Services Pre-Solicitation · W81XWH22R0025 · Posted Aug 16, 2021
- Contract value 90% obligated
- $637,486.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Reston, VA 20190, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $8,986 | |
| Funding Only Action | $256,784 | |
| Supplemental Agreement for work within scope | -$287,739 | |
| Supplemental Agreement for work within scope | $500,000 | |
| Original award | $93,769 |
About this award
Leidos, Inc., through its Leidos Services Operating Segment (doing business as SAIC), was awarded a delivery order valued at $637,486 by the Defense Health Agency on December 2, 2024, for support services to the Breast Cancer Research Program under the Congressionally Directed Medical Research Programs. The contract, with no set-aside designation, will be performed in Herndon, Virginia, and is structured as a cost-plus-fixed-fee arrangement with a completion date of December 1, 2025. The Breast Cancer Research Program challenges the scientific community to design innovative research aimed at ending breast cancer for service members, their families, veterans, and the general public.
This delivery order represents continuation of Leidos' extensive involvement in federally funded medical research support, leveraging the company's established capabilities across the Defense Health Agency and other research-focused federal agencies. Leidos Holdings, Inc., the parent company, has demonstrated significant experience in medical research program administration, psychological health research, and specialized scientific services across multiple government sectors. The award falls within Leidos' broader portfolio of contracts supporting critical military health research initiatives and underscores the company's competitive position as a prime contractor for complex government medical research support services.
Quick answers
Who was awarded contract HT942524F0281?
HT942524F0281 was awarded to Leidos, Inc. by Defense Health Agency (Department of Defense) on December 2, 2024.
How much is contract HT942524F0281 worth?
The government has obligated $571,801 on HT942524F0281. Its current value, with exercised options, is $637,486.
Is contract HT942524F0281 an order under another contract?
Yes. HT942524F0281 is a delivery order under HT942523D0002, an indefinite delivery contract.
Was contract HT942524F0281 competed?
The extent of competition for HT942524F0281 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award